What podcasts say about Food and Drug Administration
Every statement, with the speaker, the exact quote and the moment it was said.
What experts have said about Food and Drug Administration
22 statements · 12 positive · 7 negative · 3 neutral
FDA leadership uncertainty risks increasing volatility.
“I certainly think it risks more volatility”
Open the episode · Episode 204 - November 20, 2026Listen at 18:36
Regulatory uncertainty harms biotech companies.
“Uncertainty is harmful.”
Open the episode · Episode 204 - November 20, 2026Listen at 21:35
The FDA has largely maintained professional, consistent, technocratic operations.
“mostly drugs are getting approved. Our interactions with FDA have been professional. They've been thoughtful. They've been consistent. They've been technocratic”
Open the episode · Episode 204 - November 20, 2026Listen at 21:53
“I think it will be close to a record year of drug approvals”
Open the episode · Episode 204 - November 20, 2026Listen at 22:53
The FDA’s biggest need is additional staffing.
“the biggest need at the FDA is just like getting more people”
Open the episode · Episode 203 - November 13, 2026Listen at 14:44
FDA likely will lack a confirmed permanent commissioner for the rest of Trump’s administration.
“The most likely outcome is there will not be a confirmed permanent commissioner, I think, for the rest of the Trump administration.”
Open the episode · Ep. 397 - What the U.S. midterms mean for biopharmaListen at 6:44
The FDA should restore credibility, standards, and consistency.
“I want the FDA to get back to a point, right, where we kind of like... look up to the FDA and the standard and the consistency.”
Open the episode · Episode 202 - November 6, 2026Listen at 6:40
The FDA has lacked knowledge of food ingredients and their quantities.
“the FDA, up until we just closed it, did not know what's in our food, doesn't know.”
Open the episode · #2578 - Calley MeansListen at 1:59:36
The FDA plays an important global role because it is trusted on drug safety.
“The United States FDA plays a really important function globally because everyone trusts us. to be hard asses about drug safety.”
Open the episode · AI Boom Reality Check, Jobs Boom, Cybertruck Scrapped | Praveer Melwani, Keller Cliffton, Rahul Sonwalkar, Max Siegelman, D.A. WallachListen at 2:09:58
The FDA effectively protects patients and supports trust in medicines.
“the FDA, I think does a really nice job. keeping patients safe, making sure we trust the medicines we're getting.”
Open the episode · AI Boom Reality Check, Jobs Boom, Cybertruck Scrapped | Praveer Melwani, Keller Cliffton, Rahul Sonwalkar, Max Siegelman, D.A. WallachListen at 2:10:28
FDA drug approval requires evidence of both safety and effectiveness.
“for the FDA to approve a drug, they've got to believe that the company has proven it is both safe. And effective.”
Open the episode · AI Boom Reality Check, Jobs Boom, Cybertruck Scrapped | Praveer Melwani, Keller Cliffton, Rahul Sonwalkar, Max Siegelman, D.A. WallachListen at 2:10:51
Insufficient FDA diligence can allow harmful drugs onto the market before withdrawal.
“they would look into all the adverse drug deaths and all the different people that die because of these fucking drugs that... wind up getting pulled from the market because the FDA didn't do their due diligence when they passed them.”
Open the episode · #2572 - Colum TyrrellListen at 1:19:46
FDA approval for medical devices can take a decade.
“It takes a decade for the FDA to actually approve it.”
Open the episode · "You Can See Everything" Sparks Debate, 17% GDP Growth Please, Call of Duty Campaign Review | Katie Drummond, Bing Gordon, Daksh Gupta, Jean-Denis Greze, Quinten FarmerListen at 4:43
FDA’s CEDAR approved 46 novel drugs despite an 18% workforce reduction.
“Cedar approved 46 novel drugs despite an 18% reduction in force across the FDA.”
Open the episode · Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is WatchingListen at 4:14
FDA leadership changes could occur in 2027.
“I think 2027 could be the year that we see this change with the FDA.”
Open the episode · Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is WatchingListen at 6:44
FDA approval for psychedelic medicines will occur soon.
“I think it will happen soon.”
Open the episode · What Humans, Animals and Plants Tell Us About Consciousness | Michael PollanListen at 1:49:31
Advancing one compound through FDA approval costs roughly $200–250 million.
“it takes, whether we like it or not, it takes roughly $200 to $250 million to get one compound through the FDA process.”
Open the episode · #884: How to Spot 10-Year Trends and Build Billion-Dollar Companies — Kevin Ryan of DoubleClick, MongoDB, Business Insider, and Many MoreListen at 53:38
Advancing one compound through FDA approval costs roughly $200–250 million
“it takes, whether we like it or not, it takes roughly $200 to $250 million to get one compound through the FDA process.”
Open the episode · #884: How to Spot 10-Year Trends and Build Billion-Dollar Companies — Kevin Ryan of DoubleClick, MongoDB, Business Insider, and Many MoreListen at 53:38
Consumers should rely on FDA and CDC guidance during food-safety challenges.
“I'd listen to the FDA and I'd listen to the CDC.”
Open the episode · Mad Money w/ Jim Cramer 7/29/26Listen at 17:56
The FDA regulatory environment is improving.
“I'm very confident. that we're moving in the right direction from a regulatory standpoint.”
Open the episode · Mad Money w/ Jim Cramer 4/23/26Listen at 25:21
The executive order seeks to reduce breakthrough-drug review from six months to one or two.
“It takes that from even for breakthrough products, it's a six month review cycle and tries to bring that down to one or two months.”
Open the episode · Mad Money w/ Jim Cramer 4/20/26Listen at 33:00
Agilent sees steady drug approvals and favorable FDA conditions for its business.
“we see a steady release of drugs through it. So from our side, we see that it's going pretty well.”
Open the episode · Mad Money w/ Jim Cramer 11/25/25Listen at 36:06
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.